Contact
searchSearch
HMP Global
April W. Armstrong, MD
Conference Coverage
Rethinking the Role of Orals: Where TYK2 Inhibitors Fit in Psoriasis Management
10/27/2025
Jessica Garlewicz
The discussion centered on patient preferences, mechanism-driven selectivity, and a growing oral therapy pipeline that may shift long-standing practice paradigms.
The discussion centered on patient preferences, mechanism-driven selectivity, and a growing oral therapy pipeline that may shift long-standing practice paradigms.
The discussion centered on...
10/27/2025
The Dermatologist
Elizabeth (Lisa) A. Swanson, MD
Conference Coverage
Oral Therapies in Focus: Where Pills Fit in a Biologic-Dominated Psoriasis Landscape
10/24/2025
Jessica Garlewicz
This panel addressed emerging oral IL-23 inhibitors, the durability of current biologics, and patient preferences, framing the discussion around evolving treatment goals like on-treatment remission and real-world clinical needs.
This panel addressed emerging oral IL-23 inhibitors, the durability of current biologics, and patient preferences, framing the discussion around evolving treatment goals like on-treatment remission and real-world clinical needs.
This panel addressed emerging...
10/24/2025
The Dermatologist
psoriasis
Conference Coverage
Integrating GLP-1 Receptor Agonists in Psoriatic Disease: A Dual-Target Approach to Inflammation and Obesity
10/24/2025
Jessica Garlewicz
The discussion centered on the dual role of these agents in reducing systemic inflammation and promoting weight loss—2 factors strongly linked to psoriasis pathophysiology and therapeutic response.
The discussion centered on the dual role of these agents in reducing systemic inflammation and promoting weight loss—2 factors strongly linked to psoriasis pathophysiology and therapeutic response.
The discussion centered on the...
10/24/2025
The Dermatologist
psoriasis
Conference Coverage
TYK2 Inhibitors Redefine Systemic Options in Moderate-to-Severe Psoriasis: Mechanism, Selectivity, and Long-Term Response
10/24/2025
Jessica Garlewicz
This session clarified mechanistic distinctions, clinical relevance, and patient-centered endpoints, with a strong emphasis on selectivity, durability, and the evolving role of oral agents in moderate-to-severe psoriasis.
This session clarified mechanistic distinctions, clinical relevance, and patient-centered endpoints, with a strong emphasis on selectivity, durability, and the evolving role of oral agents in moderate-to-severe psoriasis.
This session clarified...
10/24/2025
The Dermatologist
psoriasis
Conference Coverage
Psoriasis Pearls With Dr Mark Lebwohl: Practical Strategies for Refractory Cases, Combinations, and Cancer Risk
10/24/2025
Jessica Garlewicz
Through patient cases and clinical anecdotes, Dr Lebwohl covered combination therapy, treatment resistance, cancer risk stratification, and drug safety considerations.
Through patient cases and clinical anecdotes, Dr Lebwohl covered combination therapy, treatment resistance, cancer risk stratification, and drug safety considerations.
Through patient cases and...
10/24/2025
The Dermatologist
psoriasis
Conference Coverage
Refining Psoriasis Treatment in High-Impact, Limited Disease: IL-23 Data and Real-World Strategies From Fall Clinical 2025
10/24/2025
Jessica Garlewicz
During their Fall Clinical 2025 session, James Q. Del Rosso, DO; Bruce Strober, MD; and E. James Song, MD, provided a detailed review of current treatment considerations for high-impact, limited psoriasis and new data on IL-23 inhibitors.
During their Fall Clinical 2025 session, James Q. Del Rosso, DO; Bruce Strober, MD; and E. James Song, MD, provided a detailed review of current treatment considerations for high-impact, limited psoriasis and new data on IL-23 inhibitors.
During their Fall Clinical 2025...
10/24/2025
The Dermatologist
Raj Chovatiya, MD, PhD
Conference Coverage
Reframing Generalized Pustular Psoriasis: From Pathogenesis to Early Clinical Intervention
10/24/2025
Jessica Garlewicz
This session emphasized how early recognition, knowledge of trigger factors, and prompt dermatologic intervention can significantly alter outcomes in what remains a life-threatening, often misdiagnosed condition.
This session emphasized how early recognition, knowledge of trigger factors, and prompt dermatologic intervention can significantly alter outcomes in what remains a life-threatening, often misdiagnosed condition.
This session emphasized how...
10/24/2025
The Dermatologist
April Armstrong, MD
Conference Coverage
Psoriasis Treatment in 2025: New Approvals, Expanded Indications, and a Push Toward Remission
10/23/2025
Jessica Garlewicz
In 2025, psoriasis care continues to evolve with new FDA approvals, expanded pediatric indications, and long-term data supporting durable efficacy and safety.
In 2025, psoriasis care continues to evolve with new FDA approvals, expanded pediatric indications, and long-term data supporting durable efficacy and safety.
In 2025, psoriasis care...
10/23/2025
The Dermatologist

Disclaimer

This content has been developed independently and is not endorsed by the 2025 Fall Clinical Dermatology Conference.

HMP Global Products

Events

HMP Education Logo
HMP Omnimedia Logo
HMP Europe Logo
© 2026 HMP Global. All Rights Reserved.
Cookie Policy Privacy Policy Terms of Use